{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:51:39Z","timestamp":1779123099339,"version":"3.51.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR076349"],"award-info":[{"award-number":["R01AR076349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR076349-S1"],"award-info":[{"award-number":["R01AR076349-S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR081040"],"award-info":[{"award-number":["R01AR081040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MaineHealth Institute for Research"},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM106391"],"award-info":[{"award-number":["P30GM106391"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121301"],"award-info":[{"award-number":["P20GM121301"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Northern New England Clinical and Translational Research Network NIH\/NIGMS","award":["U54GM115516"],"award-info":[{"award-number":["U54GM115516"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atenolol is a \u03b21-selective \u03b2-adrenergic receptor antagonist (a.k.a. \u03b2-blocker) and is under investigation in a clinical trial to prevent osteoporosis in postmenopausal women. The effects of atenolol on rodent bone are unknown, which limits research investigating mechanisms or modeling human treatment effects. However, propranolol, a non-selective \u03b2-blocker, has been widely used in rodent models. Propranolol co-treatment with intermittent truncated PTH improves a serum marker of bone formation, P1NP, while blocking the PTH-induced increase in CTX-I-MMP, a serum marker of bone resorption. To determine whether atenolol has similar properties as propranolol during co-treatment, we tested the combined effects of atenolol and PTH in female C57BL\/6J mice. Atenolol exposure was confirmed in both serum and marrow at clinically relevant levels. Atenolol had little effect on femoral or L5 vertebra microarchitecture, either on its own or in combination with PTH, which improved trabecular microarchitecture as expected. However, co-treatment with PTH significantly increased P1NP levels past that of PTH alone, suggesting longer treatment may improve bone density by increasing bone formation. In summary, we found little effect of atenolol alone or in combination with PTH, which may be related to relative selectivity of atenolol for \u03b21AR over \u03b22AR, the predominant \u03b2AR in bone. Future studies should test whether longer term atenolol may improve microarchitectural parameters with PTH co-treatment.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf087","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:25:36Z","timestamp":1747311936000},"source":"Crossref","is-referenced-by-count":2,"title":["Atenolol, alone or in combination with PTH, has a modest effect on bone in female C57BL\/6J mice"],"prefix":"10.1093","volume":"9","author":[{"given":"Rebecca L","family":"Fontaine","sequence":"first","affiliation":[{"name":"Center for Molecular Medicine, MaineHealth Institute for Research, MaineHealth , Scarborough, ME , 04074,","place":["United States"]},{"name":"Graduate School of Biomedical Science and Engineering, University of Maine , Orono, ME , 04469,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"Brooks","sequence":"additional","affiliation":[{"name":"Center for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center , Boston, MA , 02215,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Barlow","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Portland Laboratory for Biotechnology and Health Sciences, College of Osteopathic Medicine, University of New England , Portland, ME , 04103,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J","family":"Neilson","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, MaineHealth Institute for Research, MaineHealth , Scarborough, ME , 04074,","place":["United States"]},{"name":"Department of Public Health and Health Sciences, Roux Institute at Northeastern University , Portland, ME , 04101,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine W","family":"Lary","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, MaineHealth Institute for Research, MaineHealth , Scarborough, ME , 04074,","place":["United States"]},{"name":"Department of Public Health and Health Sciences, Roux Institute at Northeastern University , Portland, ME , 04101,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L","family":"Houseknecht","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Portland Laboratory for Biotechnology and Health Sciences, College of Osteopathic Medicine, University of New England , Portland, ME , 04103,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J","family":"Motyl","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine, MaineHealth Institute for Research, MaineHealth , Scarborough, ME , 04074,","place":["United States"]},{"name":"Graduate School of Biomedical Science and Engineering, University of Maine , Orono, ME , 04469,","place":["United States"]},{"name":"Tufts University School of Medicine, Tufts University , Boston, MA , 02111,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"11","key":"2025062622220403700_ref1","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1172\/JCI122151","article-title":"Sympathetic beta1-adrenergic signaling contributes to regulation of human bone metabolism","volume":"128","author":"Khosla","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"2025062622220403700_ref2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0092-8674(02)01049-8","article-title":"Leptin regulates bone formation via the sympathetic nervous system","volume":"111","author":"Takeda","year":"2002","journal-title":"Cell"},{"issue":"7032","key":"2025062622220403700_ref3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature03398","article-title":"Leptin regulation of bone resorption by the sympathetic nervous system and CART","volume":"434","author":"Elefteriou","year":"2005","journal-title":"Nature"},{"issue":"11","key":"2025062622220403700_ref4","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1210\/jc.2012-2381","article-title":"Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women","volume":"97","author":"Farr","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025062622220403700_ref5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3892\/mmr.2018.9752","article-title":"Identification of gene biomarkers in patients with postmenopausal osteoporosis","volume":"19","author":"Yang","year":"2019","journal-title":"Mol Med Rep"},{"issue":"5","key":"2025062622220403700_ref6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jbmr.4523","article-title":"Propranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL\/6J mice","volume":"37","author":"Treyball","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025062622220403700_ref7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.bone.2006.01.145","article-title":"Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice","volume":"39","author":"Pierroz","year":"2006","journal-title":"Bone"},{"issue":"1","key":"2025062622220403700_ref8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41413-024-00321-z","article-title":"Beta-receptor blocker enhances the anabolic effect of PTH after osteoporotic fracture","volume":"12","author":"Huang","year":"2024","journal-title":"Bone Res"},{"issue":"19","key":"2025062622220403700_ref9","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1073\/pnas.1109036109","article-title":"Anabolic action of parathyroid hormone regulated by the beta2-adrenergic receptor","volume":"109","author":"Hanyu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2025062622220403700_ref10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nchembio.2267","article-title":"Beta(2)-adrenergic receptor control of endosomal PTH receptor signaling via Gbetagamma","volume":"13","author":"Jean-Alphonse","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2025062622220403700_ref11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jcb.24953","article-title":"PTH regulates beta2-adrenergic receptor expression in osteoblast-like MC3T3-E1 cells","volume":"116","author":"Moriya","year":"2015","journal-title":"J Cell Biochem"},{"issue":"703","key":"2025062622220403700_ref12","doi-asserted-by":"publisher","first-page":"eabc5944","DOI":"10.1126\/scisignal.abc5944","article-title":"Spatial bias in cAMP generation determines biological responses to PTH type 1 receptor activation","volume":"14","author":"White","year":"2021","journal-title":"Sci Signal"},{"issue":"1","key":"2025062622220403700_ref13","doi-asserted-by":"publisher","first-page":"1ra","DOI":"10.1126\/scitranslmed.3000071","article-title":"A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Sci Transl Med"},{"issue":"5","key":"2025062622220403700_ref14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1124\/molpharm.121.000363","article-title":"Unique positive cooperativity between the beta-arrestin-biased beta-blocker carvedilol and a small molecule positive allosteric modulator of the beta2-adrenergic receptor","volume":"100","author":"Pani","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"8","key":"2025062622220403700_ref15","doi-asserted-by":"publisher","first-page":"e71980","DOI":"10.1371\/journal.pone.0071980","article-title":"The beta-blocker nebivolol is a GRK\/beta-arrestin biased agonist","volume":"8","author":"Erickson","year":"2013","journal-title":"PLoS One"},{"issue":"07","key":"2025062622220403700_ref16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1055\/s-2007-996283","article-title":"Characterization of the beta-adrenergic receptor mediating secretion of parathyroid hormone","volume":"12","author":"Kukreja","year":"1980","journal-title":"Horm Metab Res"},{"issue":"3","key":"2025062622220403700_ref17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/odi.13280","article-title":"Suppression of tooth movement-induced sclerostin expression using beta-adrenergic receptor blockers","volume":"26","author":"Uchibori","year":"2020","journal-title":"Oral Dis"},{"issue":"6","key":"2025062622220403700_ref18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.17219\/acem\/66291","article-title":"Effect of nebivolol on fracture healing: an experimental rat model","volume":"26","author":"Metineren","year":"2017","journal-title":"Adv Clin Exp Med"},{"issue":"9","key":"2025062622220403700_ref19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/GME.0000000000000680","article-title":"Osteogenic actions of metoprolol in an ovariectomized rat model of menopause","volume":"23","author":"Zang","year":"2016","journal-title":"Menopause"},{"issue":"5","key":"2025062622220403700_ref20","doi-asserted-by":"publisher","first-page":"E507","DOI":"10.1152\/ajpendo.00191.2012","article-title":"\u03b2-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species","volume":"304","author":"Kondo","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1-2","key":"2025062622220403700_ref21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.abb.2008.11.012","article-title":"Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms","volume":"482","author":"Aitken","year":"2009","journal-title":"Arch Biochem Biophys"},{"issue":"7","key":"2025062622220403700_ref22","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/j.1476-5381.2011.01686.x","article-title":"Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation","volume":"165","author":"Rodrigues","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2025062622220403700_ref23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1515\/cclm-2024-1148","article-title":"Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism","volume":"63","author":"Lombardi","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"2025062622220403700_ref24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF00636787","article-title":"Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration","volume":"18","author":"Leonetti","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2025062622220403700_ref25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2125.1985.tb05072.x","article-title":"A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects","volume":"20","author":"Rigby","year":"1985","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2025062622220403700_ref26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/cvr\/cvp168","article-title":"Therapeutic effect of beta-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation","volume":"84","author":"Zhan","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2025062622220403700_ref27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0022-3565(25)23517-0","article-title":"Species differences in the localization and number of CNS beta adrenergic receptors: rat versus guinea pig","volume":"249","author":"Booze","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2025062622220403700_ref28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/0006-8993(91)90752-H","article-title":"Beta-adrenergic receptor distribution in human and rat hippocampal formation: marked species differences","volume":"561","author":"Duncan","year":"1991","journal-title":"Brain Res"},{"issue":"1-3","key":"2025062622220403700_ref29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejphar.2012.12.016","article-title":"Dose effects of butoxamine, a selective beta2-adrenoceptor antagonist, on bone metabolism in spontaneously hypertensive rat","volume":"701","author":"Arai","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2025062622220403700_ref30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3906\/sag-1909-187","article-title":"Evaluation of the effects of beta1-selective beta-blockers on bone mineral density and fracture risk in postmenopausal women","volume":"50","author":"Yavuz Keles","year":"2020","journal-title":"Turk J Med Sci"},{"issue":"6","key":"2025062622220403700_ref31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.bone.2012.08.126","article-title":"Beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients","volume":"51","author":"Song","year":"2012","journal-title":"Bone"},{"issue":"3","key":"2025062622220403700_ref32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bone.2010.10.170","article-title":"Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study","volume":"48","author":"Yang","year":"2011","journal-title":"Bone"},{"issue":"3","key":"2025062622220403700_ref33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2025062622220403700_ref34","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1021\/acs.jmedchem.6b00358","article-title":"Uncoupling the structure-activity relationships of beta2 adrenergic receptor ligands from membrane binding","volume":"59","author":"Dickson","year":"2016","journal-title":"J Med Chem"},{"issue":"16","key":"2025062622220403700_ref35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat-different beta-adrenergic receptor blocker","volume":"54","author":"Munzel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025062622220403700_ref36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnins.2019.00033","article-title":"Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier","volume":"13","author":"Laurens","year":"2019","journal-title":"Front Neurosci"},{"issue":"4","key":"2025062622220403700_ref37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/0253-7613.83117","article-title":"Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension","volume":"43","author":"Badar","year":"2011","journal-title":"Indian J Pharmacol"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf087\/63193904\/ziaf087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf087\/63193904\/ziaf087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf087\/63193904\/ziaf087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:22:08Z","timestamp":1750990928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf087\/8132808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf087","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,15]]},"article-number":"ziaf087"}}